更新于：2024-11-05
Loteprednol Etabonate
氯替泼诺
更新于：2024-11-05
概要
基本信息
药物类型 小分子化药 |
别名 Loteprednol etabonate (JAN/USAN)、Loteprednol Etabonate Ophthalmic Suspension、CDDD-5604 + [13] |
作用机制 GR激动剂(糖皮质激素受体激动剂)、cPLA2α 激动剂(胞内磷脂酶A2 激动剂) |
非在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C24H31ClO7 |
InChIKeyDMKSVUSAATWOCU-HROMYWEYSA-N |
CAS号82034-46-6 |
关联
69
项与 氯替泼诺 相关的临床试验The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain
A Multicentric Randomized Double Blind Double Dummy Parallel Group Two Arm Comparative Phase III Clinical Study to Evaluate Efficacy Safety and Tolerability of Loteprednol Etabonate Ophthalmic Suspension 1% w/v of Ajanta Pharma Ltd versus Loteprednol Etabonate Ophthalmic Suspension 0.5% w/v in treatment of Post-Operative Inflammatory conditions of Eye - Phase III
The CLEAN Study: Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization-A Prospective Cohort Study of Combination Therapy in the Treatment of Dry Eye
100 项与 氯替泼诺 相关的临床结果
登录后查看更多信息
100 项与 氯替泼诺 相关的转化医学
登录后查看更多信息
100 项与 氯替泼诺 相关的专利（医药）
登录后查看更多信息
244
项与 氯替泼诺 相关的文献（医药）2024-10-20Ocular immunology and inflammation
Improvement of Clinical Findings, Meibography and Tear Film Parameters in Pediatric Ocular Rosacea Patients After a Standard Treatment Protocol
Article
作者: Onal, Irem ; Yildirim, Yusuf ; Aydin, Fahri Onur ; Mergen, Burak ; Ceylan, Ali
PURPOSE:
The objective of this study was to illustrate the changes in ocular findings, meibography, and tear break-up time (TBUT) values in pediatric patients with ocular rosacea following a standardized treatment.
METHODS:
The study included consecutive patients diagnosed with ocular rosacea, referred to a tertiary hospital between 2021 and 2023. Each patient underwent biomicroscopic examinations, non-invasive TBUT assessments, corneal fluorescein staining (evaluated using the Oxford scoring system), and meibography. The standard treatment protocol involved warm compresses, eyelid hygiene, preservative-free sodium hyaluronate eye drops (administered four times daily), topical azithromycin 1.5% (twice daily for 3 days), topical steroids (loteprednol 0.5%, four times daily for 2 weeks), and either doxycycline 100 mg/day for 14 days or oral suspension of azithromycin 10 mg/kg for 3 days followed by an additional three-day course of treatment administered 10 days later (for patients above and below 14 years of age, respectively).
RESULTS:
The study included 18 patients, with 10 (55.5%) being female and 8 (44.4%) being male, with a mean age of 9.7 ± 4.5 years (range: 3-18). Four patients displayed cutaneous involvement. The treatments resulted in significant improvements in the Oxford scores, reduction in corneal neovascularization, and increased TBUT (p < 0.001, p = 0.016, p < 0.001, respectively). Meibomian gland loss area also significantly improved post-treatment (27.4 ± 6.7% vs 39.2 ± 13.4%, p = 0.001).
CONCLUSION:
This study demonstrated that pediatric ocular rosacea patients may exhibit improved meibomian gland function, regression of corneal neovascularization, and enhanced tear film parameters following a standardized treatment protocol that includes both topical and systemic approaches.
2024-08-01Cornea
Prospective Assessment of Loteprednol Etabonate 0.25% for Prevention of Immunologic Rejection After Descemet Membrane Endothelial Keratoplasty in Eyes With Fuchs Dystrophy
Article
作者: Feng, Matthew T ; Price, Marianne O ; Gang, Anjulie ; Price, Francis W
Purpose::
The purpose of this study was to assess off-label use of loteprednol etabonate 0.25% ophthalmic suspension for prevention of immunologic rejection after Descemet membrane endothelial keratoplasty (DMEK).
Methods::
This prospective, open-label study enrolled 70 eyes of 70 participants without preexisting glaucoma 1 month after DMEK. Participants used topical loteprednol 0.25% 4 times daily for 2 months, tapered by 1 drop/month to once daily use, and continued use through 1 year after DMEK. Main outcomes were rate of intraocular pressure (IOP) elevation (defined as a relative increase of ≥10 mm Hg over the pretransplant IOP) and rate of initial allograft rejection episodes. The results were compared with historical data using the log-rank test.
Results::
All participants had Fuchs dystrophy, and 40 of 70 (57%) were female. None (0%) experienced an immunologic graft rejection episode, matching the previously reported efficacy of prednisolone acetate 1% suspension and loteprednol 0.5% gel (both 0% incidence). One study eye developed IOP elevation 3 months after DMEK (cumulative risk 1.5%). Compared with historical data, this was similar to the risk with loteprednol 0.5% gel (4%, P = 0.36) and significantly lower than the risk with prednisolone 1% suspension (18%, P = 0.0025). Two participants (3%) complained of instillation site discomfort, consistent with the 5% rate reported on package labeling.
Conclusions::
Loteprednol 0.25% suspension, approved for short-term treatment of dry eyes, effectively prevented immunologic rejection episodes with minimal risk of IOP elevation when used from 1 month until 12 months after DMEK in patients without preexisting glaucoma.
2024-03-01Journal of cataract and refractive surgery
Anti-inflammatory medication use after cataract surgery: online survey of practice patterns
Article
作者: Srikumaran, Divya ; Chang, David F ; Riaz, Kamran M ; Prescott, Christina R ; Awidi, Abdelhalim A ; Daoud, Yassine J ; Woreta, Fasika A ; Li, Ximin ; Zebardast, Nazlee ; LaBorwit, Scott
Purpose::
To determine current prescribing patterns for topical or intraocular/periocular anti-inflammatory medications (AIMs) after routine cataract surgery.
Setting::
kera-netonline members.
Design::
Cross-sectional survey.
Methods::
An online survey was distributed to subscribers ofkera-net, a global online platform sponsored by the Cornea Society. Questions were asked regarding the use of topical or intraocular/periocular AIM after cataract surgery and types of medications prescribed.
Results::
Of 217 surgeon respondents (23% response rate), 171 (79%) practiced in the United States and 171 (79%) were cornea subspecialists. Most of the respondents (n = 196, 97%) prescribed topical corticosteroids after routine cataract surgery. The most frequently prescribed were prednisolone acetate (n = 162, 83%), followed by dexamethasone (n = 26, 13%), difluprednate (n = 24, 12%), and loteprednol etabonate (n = 13, 7%). Corticosteroids comprised (n = 40, 32%) of total intraocular/periocular injections, with triamcinolone acetonide 10 or 40 mg (n = 19, 47.5%) most commonly used. 23 surgeons (58%) who utilized intraocular/periocular corticosteroids also prescribed topical corticosteroids. Topical nonsteroidal anti-inflammatory drugs were prescribed postoperatively by 148 surgeons (73%).
Conclusions::
Most surgeons prescribed topical AIM after routine cataract surgery. Many surgeons injected intraocular or periocular AIM while prescribing topical AIM. The diversity of practice patterns may reflect the lack of clear evidence-based guidelines.
100 项与 氯替泼诺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 干眼综合征 | 美国 | 2020-10-26 | |
| 疼痛 | 美国 | 2011-04-15 | |
| 变应性结膜炎 | 中国 | 2007-01-10 | |
| 眼带状疱疹 | 中国 | 2007-01-10 | |
| 角膜炎 | 中国 | 2007-01-10 | |
| 睫状体炎 | 美国 | 1998-03-09 | |
| 虹膜炎 | 美国 | 1998-03-09 | |
| 疱疹性角膜炎 | 美国 | 1998-03-09 | |
| 眼部炎症 | 美国 | 1998-03-09 | |
| 术后炎症 | 美国 | 1998-03-09 | |
| 玫瑰痤疮 | 美国 | 1998-03-09 | |
| 季节性过敏性结膜炎 | 美国 | 1998-03-09 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 眼睛疼痛 | 临床3期 | 美国 | 2016-06-01 | |
| 干燥综合征性角膜结膜炎 | 临床3期 | 美国 | 2016-06-01 | |
| 眼部感染 | 临床3期 | 美国 | 2014-05-01 | |
| 睑缘炎 | 临床3期 | 新加坡 | 2009-10-01 | |
| 睑缘炎相关角结膜病变 | 临床3期 | 新加坡 | 2009-10-01 | |
| 白内障 | 临床3期 | 美国 | 2008-03-01 | |
| 睑板腺功能障碍 | 临床2期 | 美国 | 2014-07-01 | |
| 术后并发症 | 临床1期 | 加拿大 | 2018-04-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 70 | 齋餘齋願鏇窪膚簾襯衊(鹹構鏇糧衊壓窪製遞構) = 壓鹹網鏇鑰廠鬱鏇餘壓 觸網範簾蓋願廠窪糧鹽 (廠範鹹簾鏇網蓋鬱淵鑰, 醖鹽網簾糧齋範鏇遞壓 ~ 餘憲範壓鹽淵鬱夢製顧) 更多 | - | 2024-08-14 | |||
临床4期 | 70 | Loteprednol Etabonate 0.25% ophthalmic suspension | 鹹網夢觸艱夢餘鹹製鹽(淵製齋製憲顧憲醖積製) = 獵繭顧鏇築顧獵鹹鑰醖 壓壓鹹積網製壓積獵簾 (壓膚鹽夢窪鹹壓遞鬱鏇 ) 更多 | 积极 | 2024-08-01 | ||
临床4期 | 30 | (Restasis and Lotemax) | 膚遞窪壓願構網製膚製(餘壓製構簾選鏇衊廠糧) = 餘夢鏇鑰願鹹積顧夢鬱 製憲築齋選廠觸鏇衊積 (繭憲餘壓壓艱艱膚壓憲, 觸鹽繭積鹹鹽簾衊築鬱 ~ 獵積窪願範艱選鏇窪壓) 更多 | - | 2023-10-11 | ||
(Restasis and Dextenza) | 膚遞窪壓願構網製膚製(餘壓製構簾選鏇衊廠糧) = 範願憲襯齋鬱獵製糧繭 製憲築齋選廠觸鏇衊積 (繭憲餘壓壓艱艱膚壓憲, 鑰範鏇淵構積艱膚糧廠 ~ 餘鑰築醖願積構膚獵鑰) 更多 | ||||||
临床4期 | 37 | (Lotemax) | 膚築積膚選構蓋願廠衊(艱憲窪鏇獵夢淵觸憲鏇) = 積鏇衊鹹選願鹽鑰鬱顧 觸衊鹽鏇製獵鹽襯夢遞 (艱醖觸鏇鏇觸憲憲糧鹹, 憲簾膚顧積鑰獵構齋壓 ~ 構醖鏇艱衊鹽獵願觸繭) 更多 | - | 2022-03-23 | ||
(Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)) | 膚築積膚選構蓋願廠衊(艱憲窪鏇獵夢淵觸憲鏇) = 憲夢選簾衊醖鑰糧糧衊 觸衊鹽鏇製獵鹽襯夢遞 (艱醖觸鏇鏇觸憲憲糧鹹, 構鹹壓網鬱憲淵簾糧壓 ~ 鏇膚獵觸製獵齋網糧鹽) 更多 | ||||||
N/A | 100 | 觸獵醖鏇顧選鏇鏇獵壓(繭鑰製淵鑰願鏇鹹簾醖) = 鏇網觸繭淵觸醖鹽鹹衊 鏇壓蓋鏇齋壓醖選鹹蓋 (壓襯鹹構構觸齋鬱醖繭 ) | - | 2021-11-13 | |||
Loteprednol 0.5% | 觸獵醖鏇顧選鏇鏇獵壓(繭鑰製淵鑰願鏇鹹簾醖) = 鏇簾製範選選鹹憲鏇鹹 鏇壓蓋鏇齋壓醖選鹹蓋 (壓襯鹹構構觸齋鬱醖繭 ) | ||||||
N/A | - | - | Loteprednol Etabonate Eluting Adhesive Ocular Patch | 鹹積壓壓觸繭衊鬱膚齋(夢餘構衊鹽網衊蓋鏇鑰) = 網遞襯鹽觸餘糧艱餘齋 遞壓餘醖餘鬱鹽簾襯獵 (衊膚顧遞範鹽製衊鬱積 ) 更多 | - | 2021-06-01 | |
N/A | - | - | 蓋獵糧廠夢衊築選鹹廠(衊願選餘壓醖糧餘膚餘) = 遞簾範夢夢觸糧願糧選 願鹹築壓遞簾鏇鑰構醖 (觸淵衊鑰鹽鏇糧範觸選, 1.3) | - | 2021-06-01 | ||
蓋獵糧廠夢衊築選鹹廠(衊願選餘壓醖糧餘膚餘) = 淵網遞糧窪鏇襯夢鹹憲 願鹹築壓遞簾鏇鑰構醖 (觸淵衊鑰鹽鏇糧範觸選, 1.39) | |||||||
临床3期 | 901 | (KPI-121 0.25% Ophthalmic Suspension) | 鹽選獵鹹製醖餘淵簾淵(夢膚廠構網鹽餘膚鏇觸) = 蓋壓鏇憲顧鑰餘膚築觸 醖網齋遞齋夢齋壓窪窪 (積構網範衊齋衊顧鹹鹹, 觸憲餘衊範廠選繭艱鏇 ~ 繭鑰範構顧淵蓋獵遞繭) 更多 | - | 2021-04-02 | ||
Vehicle (Vehicle of KPI-121 0.25% Ophthalmic Suspension) | 鹽選獵鹹製醖餘淵簾淵(夢膚廠構網鹽餘膚鏇觸) = 選壓襯簾願網遞餘選鏇 醖網齋遞齋夢齋壓窪窪 (積構網範衊齋衊顧鹹鹹, 網範醖鹹膚繭鏇顧製衊 ~ 鏇構鹹繭夢觸範醖獵鹹) 更多 | ||||||
临床2期 | 206 | Vehicle (Vehicle) | 構範獵鑰繭範網夢顧糧(獵願網構網積網壓齋淵) = 齋鏇繭鬱獵餘選鏇選襯 餘遞蓋膚遞獵製鑰艱糧 (壓積夢鏇繭遞艱獵鑰齋, 顧襯觸獵醖壓鬱膚廠遞 ~ 淵構窪窪繭製艱壓構醖) 更多 | - | 2021-01-11 | ||
(KPI-121 0.25% Ophthalmic Suspension) | 構範獵鑰繭範網夢顧糧(獵願網構網積網壓齋淵) = 獵襯簾衊糧觸憲鏇糧糧 餘遞蓋膚遞獵製鑰艱糧 (壓積夢鏇繭遞艱獵鑰齋, 憲夢範醖範選築淵築衊 ~ 鹽鏇醖鑰繭醖糧鏇遞選) 更多 | ||||||
临床2期 | 150 | (KPI-121 0.25% Ophthalmic Suspension) | 鹽構獵觸淵鏇鹽範獵憲(壓窪選願範獵衊蓋觸觸) = 鹹範襯簾窪壓遞獵鏇齋 選窪淵淵選餘構選膚構 (壓壓齋築繭蓋範範餘網, 廠憲鏇願範齋齋繭夢壓 ~ 構醖鹽網鬱窪築繭簾積) 更多 | - | 2021-01-06 | ||
Placebo (Vehicle) | 鹽構獵觸淵鏇鹽範獵憲(壓窪選願範獵衊蓋觸觸) = 遞繭簾衊膚餘繭膚鏇廠 選窪淵淵選餘構選膚構 (壓壓齋築繭蓋範範餘網, 醖網膚選糧獵繭夢範網 ~ 鹹蓋願繭選餘蓋觸窪簾) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用